Introduction
Liposem 2 mg (Saroglitazar Magnesium) Tablet is a cutting-edge, dual-action prescription medication designed to address diabetic dyslipidemia and hypertriglyceridemia in adults with Type 2 diabetes mellitus uncontrolled by statin therapy. Manufactured by Everest Pharmaceuticals Ltd and supplied by Saif Pharma, this innovative therapy combines PPAR-alpha and PPAR-gamma agonism to improve lipid profiles and glycemic control simultaneously. Clinically proven to reduce harmful cholesterol, lower triglycerides, and enhance insulin sensitivity, Liposem 2 mg is a trusted choice for managing complex metabolic disorders.
Key Benefits & Clinical Efficacy
- Dual Lipid & Glucose Management:
- Reduces triglycerides (TG), LDL cholesterol, VLDL cholesterol, and non-HDL cholesterol.
- Increases HDL cholesterol (the “good” cholesterol).
- Lowers fasting plasma glucose and HbA1c levels for better diabetes control.
- Mechanism of Action:
- PPARα Activation: Enhances fatty acid oxidation, reduces TG synthesis, and boosts HDL.
- PPARγ Activation: Improves insulin sensitivity, reduces hepatic glucose output, and promotes glucose utilization.
- Proven Safety: Mild-to-moderate side effects (e.g., gastritis, asthenia) with low discontinuation rates in clinical trials.
Dosage & Administration
- Adults: 2 mg once daily (two 1 mg tablets).
- Pediatric & Geriatric Use: Not recommended for patients under 18; use cautiously in elderly patients due to comorbidities.
Safety Profile
- Contraindications: Hypersensitivity to Saroglitazar or excipients.
- Pregnancy/Lactation: Category C – Use only if benefits outweigh risks. Avoid during breastfeeding.
- Precautions: Monitor patients with liver/renal impairment, cardiac disease, or congestive heart failure.
Manufacturer & Supplier
- Manufacturer: Everest Pharmaceuticals Ltd – A renowned name in pharmaceutical innovation, Everest specializes in high-quality, research-driven therapies for metabolic and cardiovascular disorders.
- Supplier: Saif Pharma – A trusted distributor committed to delivering authentic, compliant medications to healthcare providers and pharmacies worldwide.
Why Choose Liposem 2 mg?
- Dual-Target Therapy: Addresses both lipid abnormalities and insulin resistance.
- Clinically Validated: Supported by 12-24 week phase III trials demonstrating efficacy and tolerability.
- Minimal Drug Interactions: No significant CYP450 enzyme interference, ensuring safer co-administration with other medications.
Conclusion
For patients with Type 2 diabetes struggling with uncontrolled diabetic dyslipidemia or hypertriglyceridemia, Liposem 2 mg (Saroglitazar Magnesium) Tablet offers a scientifically backed, dual-mechanism solution. Manufactured by Everest Pharmaceuticals Ltd and supplied reliably by Saif Pharma, this therapy bridges the gap between lipid management and glycemic control. Consult your healthcare provider to determine if Liposem 2 mg is right for your treatment plan.
